OGEN (oragenics.com) Net Profit

OGEN (oragenics.com) - company brandmark

Oragenics, Inc. (OGEN) is developing a nasal neuroprotection system for emergency brain injury care. The company's net profit margin reached a local peak, after which robotic bioscreening accelerated the search for antiviral agents. Current development relies on the results of intranasal drug tests, and the indicator remains around -0.01, confirming the business's financial stability given current R&D expenditures.

OGEN (Oragenics) Net Profit history from 07/04/2022 to 10/31/2026

Financial and market metric breakdowns for Oragenics (OGEN)

- price and consensus price forecast:
Stock Quotes oragenics.com|OGEN - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Oragenics, Inc.|OGEN - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Oragenics|OGEN - Book Capitalization|Market Capitalization to Book Value oragenics.com|OGEN - Aggregate Company Assets
- debt and solvency information:
Debt to Equity Ratio Oragenics, Inc.|OGEN - Long-Term Debt to Capital|Current Liabilities to Equity Oragenics Inc.|OGEN - Company Aggregate Debts|Debts to Book Value Oragenics, Inc.|OGEN - Company Long-Term Debts|Company Current Liabilities Oragenics|Intermediate Liquidity Ratio oragenics.com
- net income and valuation multiples indicators:
OGEN - Net Profit
Fundamental valuation:OGEN oragenics.com
Brand item of Oragenics Inc.

Oragenics, Inc. (OGEN) brings together leading vaccine and infection specialists to develop protection against respiratory threats based on a powerful R&D complex. This indicator captures net profit by recalculating earnings based on the market value of shares, allowing the investor to assess the balance between yield and drawdown risk through the magnitude of the company's net income.

Direct competitors

Net Income Summit Pharma|MRNA (Moderna, Inc.) - Net Profit|Net Profit vaxcyte.com|Net Income TARS (Tarsus Pharmaceuticals, Inc.)|CRMD (CorMedix Inc) - Final Profit|Net Profit MCRB (Seres)|Net Financial Result Spero Pharma (SPRO)|SCYX - Company Net Income|ANTX (AN2 Therapeutics, Inc.) - Company Profit|PYPD: Net Profit|Profit After Tax LSB (LakeShore Biopharma Co., Ltd.)|ITRM (Iterum Therapeutics PLC) - Net Profit|Company Net Income BiomX Ltd PHGE|Net Profit SNGX|Net Income 60degreespharma.com SXTP|Onconetix - Net Income|Profit After Payment of Taxes OPGN (OpGen Inc)